Rising Prevalence Of Respiratory Diseases Driving Demand For Pulmonary Drugs Due To Increasing Infectious Disease Burden Is Supporting Development Across The Pulmonary Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Pulmonary Drugs Market Between 2026 And 2030?

The pulmonary drugs market size has experienced significant growth in recent years. It is projected to expand from $56.98 billion in 2025 to $60.07 billion in 2026, registering a compound annual growth rate (CAGR) of 5.4%. The historical market expansion can be attributed to factors such as increasing asthma prevalence, rising COPD incidence, the growth of urban air pollution, the expansion of inhalation drug delivery methods, and improved diagnosis of respiratory diseases.

The pulmonary drugs market size is anticipated to exhibit robust growth over the next few years. It is projected to reach $74.14 billion in 2030, displaying a compound annual growth rate (CAGR) of 5.4%. This expansion in the forecast period can be attributed to an aging population’s growth, the spread of biologic pulmonary drugs, the adoption of precision respiratory medicine, an increase in smoking-related disorders, and improved access to inhaled therapies. Major trends expected during this period include a rising uptake of targeted respiratory treatments, the expansion of combination inhalation therapies, a heightened focus on long-term disease management, the broadening of biologic-based pulmonary drugs, and a shift towards personalized respiratory care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Key Growth Drivers Are Influencing The Pulmonary Drugs Market?

The expanding occurrence of respiratory illnesses is projected to fuel the expansion of the pulmonary drugs market in the future. These disorders are defined as health conditions impacting the lungs and airways, which hinder regular breathing and the exchange of oxygen. The rise in respiratory disorders is linked to the increasing rate of smoking, resulting in damage to the lungs and the development of chronic illnesses. Pulmonary drugs are vital in treating respiratory conditions by enhancing lung performance, diminishing inflammation, and easing airway blockages to facilitate improved respiration. As an illustration, in May 2025, the Centers for Disease Control and Prevention, a US-based government agency, stated that for 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, showing higher figures in women (4.1%) compared to men (3.4%). The prevalence of COPD climbed significantly with advancing age, escalating from 0.4% in adults 18–24 to 10.5% in those 75 and older. Consequently, the escalating number of respiratory diseases is stimulating the expansion of the pulmonary drugs market.

What Are The Major Segment Categories Within The Pulmonary Drugs Market?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Trends Are Impacting The Pulmonary Drugs Market?

Companies operating in the pulmonary drugs market are prioritizing therapeutic advancements, notably focusing on dual PDE3 and PDE4 inhibition delivered via inhalation. This innovation seeks to integrate bronchodilator and non-steroidal anti-inflammatory benefits into a single molecule for the sustained management of chronic obstructive pulmonary disease (COPD). Dual PDE3 and PDE4 inhibition facilitates simultaneous airway relaxation and decreased lung inflammation, thereby more effectively addressing persistent COPD symptoms than conventional treatments and streamlining administration. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, obtained U.S. FDA approval for Ohtuvayre (ensifentrine), representing the first inhaled therapy with this dual-mechanism profile in over 20 years. Delivered via a standard jet nebulizer, Ohtuvayre provides both bronchodilator and anti-inflammatory effects in one dose, having shown clinical efficacy as a monotherapy and in conjunction with other maintenance treatments in the Phase 3 ENHANCE trials, and is projected to be accessible through specialty pharmacies in the U.S. by the third quarter of 2024.

Which Companies Are Influencing The Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Access The Complete Pulmonary Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

What Is The Largest Regional Market In The Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pulmonary Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Browse Through More Reports Similar to the Global Pulmonary Drugs Market 2026, By The Business Research Company

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795